Genetic Association and Risk Scores in a Chronic Obstructive
Pulmonary Disease Meta-analysis of 16,707 Subjects by Busch, Robert et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
U.S. Department of Veterans Affairs Staff
Publications U.S. Department of Veterans Affairs
2017
Genetic Association and Risk Scores in a Chronic
Obstructive Pulmonary Disease Meta-analysis of
16,707 Subjects
Robert Busch
Brigham and Women's Hospital, rbusch@partners.org
Brian D. Hobbs
Brigham and Women's Hospital
Jin Zhou
University of Arizona
Peter J. Castaldi
Brigham and Women's Hospital
Michael J. McGeachie
Brigham and Women's Hospital
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/veterans
This Article is brought to you for free and open access by the U.S. Department of Veterans Affairs at DigitalCommons@University of Nebraska -
Lincoln. It has been accepted for inclusion in U.S. Department of Veterans Affairs Staff Publications by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.
Busch, Robert; Hobbs, Brian D.; Zhou, Jin; Castaldi, Peter J.; McGeachie, Michael J.; Hardin, Megan E.; Hawrylkiewicz, Iwona;
Sliwinski, Pawel; Yim, Jae-Joon; Kim, Woo Jin; Kim, Deog K.; Agusti, Alvar; Make, Barry J.; Crapo, James D.; Calverley, Peter M.;
Donner, Claudio F.; Lomas, David A.; Wouters, Emiel F.; Vestbo, Jorgen; Tal-Singer, Ruth; Bakke, Per; Gulsvik, Amund; Litonjua,
Agusto A.; Sparrow, David; Pare, Peter D.; Levy, Robert D.; Rennard, Stephen I.; Beaty, Terri H.; Hokanson, John; Silverman, Edwin
K.; and Cho, Michael H., "Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707
Subjects" (2017). U.S. Department of Veterans Affairs Staff Publications. 103.
http://digitalcommons.unl.edu/veterans/103
Authors
Robert Busch, Brian D. Hobbs, Jin Zhou, Peter J. Castaldi, Michael J. McGeachie, Megan E. Hardin, Iwona
Hawrylkiewicz, Pawel Sliwinski, Jae-Joon Yim, Woo Jin Kim, Deog K. Kim, Alvar Agusti, Barry J. Make, James
D. Crapo, Peter M. Calverley, Claudio F. Donner, David A. Lomas, Emiel F. Wouters, Jorgen Vestbo, Ruth Tal-
Singer, Per Bakke, Amund Gulsvik, Agusto A. Litonjua, David Sparrow, Peter D. Pare, Robert D. Levy,
Stephen I. Rennard, Terri H. Beaty, John Hokanson, Edwin K. Silverman, and Michael H. Cho
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/veterans/103
&get_box_var;ORIGINAL RESEARCH
Genetic Association and Risk Scores in a Chronic Obstructive
Pulmonary Disease Meta-analysis of 16,707 Subjects
Robert Busch1, Brian D. Hobbs1, Jin Zhou2, Peter J. Castaldi1, Michael J. McGeachie1, Megan E. Hardin1,
Iwona Hawrylkiewicz3, Pawel Sliwinski3, Jae-Joon Yim4, Woo Jin Kim5, Deog K. Kim6, Alvar Agusti7, Barry J. Make8,
James D. Crapo8, Peter M. Calverley9, Claudio F. Donner10, David A. Lomas11, Emiel F. Wouters12, Jørgen Vestbo13,
Ruth Tal-Singer14, Per Bakke15, Amund Gulsvik15, Augusto A. Litonjua1, David Sparrow16, Peter D. Pare´17,
Robert D. Levy17, Stephen I. Rennard18, Terri H. Beaty19, John Hokanson20, Edwin K. Silverman1, and Michael H. Cho1;
for the National Emphysema Treatment Trial Genetics, Evaluation of COPD Longitudinally to Identify Predictive
Surrogate End-Points, International COPD Genetics Network, and COPDGene Investigators*
1Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; 2University of Arizona,
Tucson, Arizona; 3National Tuberculosis and Lung Disease Research Institute, Warsaw, Poland; 4Division of Pulmonary and Critical
Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; 5Kangwon National
University, Chuncheon, Korea; 6Seoul National University College of Medicine Boramae Medical Center, Seoul, Korea; 7Thorax
Institute, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain; 8National Jewish Health, Denver,
Colorado; 9University of Liverpool, Liverpool, United Kingdom; 10Mondo Medico di I.F.I.M. srl, Multidisciplinary and Rehabilitation
Outpatient Clinic, Borgomanero, Novara, Italy; 11University College London, London, United Kingdom; 12University Hospital Maastricht,
Maastricht, the Netherlands; 13University of Manchester, Manchester, United Kingdom; 14GlaxoSmithKline Research and Development,
King of Prussia, Pennsylvania; 15University of Bergen, Bergen, Norway; 16Brigham and Women’s Hospital and the Veterans
Administration Medical Center–Jamaica Plain, Jamaica Plain, Massachusetts; 17Respiratory Division, Department of Medicine,
University of British Columbia, Vancouver, British Columbia, Canada; 18University of Nebraska Medical Center, Omaha,
Nebraska; 19Department of Epidemiology, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland;
and 20Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
ORCID IDs: 0000-0003-0820-7164 (R.B.); 0000-0001-9564-0745 (B.D.H.); 0000-0002-4907-1657 (M.H.C.).
Abstract
The heritability of chronic obstructive pulmonary disease (COPD)
cannot be fully explained by recognized genetic risk factors identified
as achieving genome-wide significance. In addition, the combined
contribution of genetic variation to COPD risk has not been fully
explored. We sought to determine: (1) whether studies of variants
from previous studies of COPD or lung function in a larger sample
could identify additional associated variants, particularly for severe
COPD; and (2) the impact of genetic risk scores on COPD. We
genotyped 3,346 single-nucleotide polymorphisms (SNPs) in 2,588
cases (1,803 severe COPD) and 1,782 control subjects from four
cohorts, and performed association testing with COPD, combining
these results with existing genotyping data from 6,633 cases (3,497
severe COPD) and 5,704 control subjects. In addition, we developed
genetic risk scores from SNPs associated with lung function and
COPD and tested their discriminatory power for COPD-related
measures. We identified significant associations between SNPs near
PPIC (P = 1.283 1028) and PPP4R4/SERPINA1 (P = 1.013 1028)
and severe COPD; the latter association may be driven by
recognized variants in SERPINA1. Genetic risk scores based on SNPs
previously associated with COPD and lung function had a modest
ability to discriminate COPD (area under the curve,z0.6), and
accounted for a mean 0.9–1.9% lower forced expiratory volume in
1 second percent predicted for each additional risk allele. In a large
genetic association analysis, we identified associations with severe
COPD near PPIC and SERPINA1. A risk score based on combining
genetic variants had modest, but significant, effects on risk of
COPD and lung function.
Keywords: chronic obstructive pulmonary disease; genetic
epidemiology; genetic risk factors; alpha-1 antitrypsin; genetic risk score
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Chronic obstructive pulmonary disease (COPD),
a progressive lung disease characterized
by irreversible airflow obstruction, is a
leading cause of morbidity and mortality
worldwide (1, 2). Although cigarette
smoking is the major determinant of COPD
susceptibility in the industrialized world
(3–5), pulmonary response to cigarette
smoking is highly variable (6). Genetic
factors contribute to variability in response
to smoking, and multiple studies have
identified genetic variants associated with
increased COPD susceptibility (7–12).
Nonetheless, the majority of estimated
heritability for risk to COPD remains
unexplained (13). In addition, the effect
of several recognized risk alleles on lung
function or risk of COPD, particularly in
cohorts of severely affected subjects, has not
been well studied. Meta-analysis of genetic
associations across multiple cohorts has the
advantage of improving power to detect
additional susceptibility risk variants by
combining information across studies,
which may add to our understanding
of disease mechanisms (14), as well as
providing potential new targets for COPD
therapy development (15, 16).
This study had two primary goals. First,
we wished to investigate a panel of variants
in a larger meta-analysis of cross-sectional
data to increase our power to detect
associations (17) with moderate-to-severe
and severe COPD. The marker panel
was composed of two groups of single-
nucleotide polymorphisms (SNPs). The
first group included top associations from
previous genome-wide association studies
(GWASs), including SNPs that did not
reach genome-wide significance (18), and
the second group included genetic variants
hypothesized to affect COPD (19), including
SNPs previously associated with lung function
(20–22). We hypothesized some of these loci
would reach predefined levels of statistical
significance with our additional sample size in
this meta-analysis.
Because genetic variation is fixed at
birth, genetic risk scores in cross-sectional
data may offer a way to consolidate genetic
information (23) into a clinically meaningful
tool that could help clinicians to predict
disease susceptibility, progression, and
outcomes (24, 25). Our second goal was
to determine the relevance of genetic risk
scores to COPD by modeling the effect of
COPD- and lung function–associated risk
alleles on clinical status, severe COPD-
affection status, and forced expiratory
volume in 1 second (FEV1) % predicted. We
hypothesized that a combined risk score
composed of SNPs shown to influence risk
to COPD and lung function would explain
the genetic contribution to COPD-related
outcomes in a clinically useful manner.
Materials and Methods
We performed genetic meta-analysis using
eight cohorts, including a total of 16,707
subjects (Table 1). We genotyped 3,346
SNPs (see the online supplement) in
5,358 subjects from 4 cohorts: the
Transcontinental COPD Genetics Study
(TCGS)–Korea and TCGS-Poland (26),
the International COPD Genetics Network
(ICGN) (27, 28), and the Boston Early-
Onset COPD Study (29). To maximize
power for meta-analysis, we combined these
results with existing data from five additional
cohorts: COPDGene non-Hispanic whites
and African Americans (30), Evaluation of
COPD Longitudinally to Identify Predictive
Surrogate End-Points (ECLIPSE) (31),
National Emphysema Treatment Trial
(NETT) (32)/Normative Aging Study (NAS)
(33), and Genetics of COPD in Norway
(GenKOLS) (34). Detailed descriptions
of these cohorts have been previously
published (35).
All subjects were current or former
cigarette smokers with and without COPD,
except for the Early-Onset COPD Study,
which included a small number of
nonsmokers. We defined “moderate to
severe” COPD as GOLD (Global Initiative
for Chronic Obstructive Lung Disease) (2)
spirometric grade II–IV COPD (post-
bronchodilator FEV1/forced vital capacity
[FVC], 0.7, FEV1, 80% predicted),
whereas “severe” COPD was defined as
grades III–IV COPD (FEV1/FVC, 0.7,
FEV1, 50% predicted). Controls had
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Clinical Relevance
In meta-analyses of a chronic
obstructive pulmonary disease
(COPD) genome-wide association
study involving over 16,000 subjects,
we found two single-nucleotide
polymorphisms (SNPs; rs112458284
and rs6860095) not previously
described in genome-wide studies that
were associated with Global Initiative
for Chronic Obstructive Lung Disease
spirometric stage III–IV COPD at
genome-wide significance levels. One
of these likely tags the SERPINA1 Z
allele based on its linkage
disequilibrium pattern and conditional
analysis results. In addition, we
describe two genetic risk scores based on
COPD- and lung function–associated
SNPs and show their applications in
explaining COPD severity and COPD
affection status risk.
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normal spirometry (FEV1/FVC> 0.7,
FEV1> 80%). Previously diagnosed alpha-1
antitrypsin deficiency was an exclusion
criterion for all cohorts.
Genetic Analysis
We used PLINK v1.9 (36) and GWAF (37)
for case–control and family-based data,
respectively, to perform multiple logistic
regression within each dataset and then
performed fixed-effect meta-analysis
using METAL (38). Given that many of
our SNPs were chosen from top findings
from prior GWASs (see Table E1 in the
online supplement for full list of SNPs
and provenance), we required an overall
P value of less than 53 1028 for statistical
significance. We also considered a more
liberal suggestive threshold based on a
Bonferroni correction for the number
of tested SNPs (P, 1.493 1025).
Genetic Risk Scores
We used PLINK v1.9 to create genetic scores
based on significant associations from prior
GWASs of COPD and lung function (20, 21,
39). We oriented risk alleles to be consistent
with prior reports, and gave each allele equal
weight. We applied these scoring systems
to the ICGN cohort, the largest individual
cohort not used in the discovery of any of
the risk score variants. Risk scores were also
applied to the COPDGene and TCGS
Poland cohorts using analogous methods.
The resultant risk scores were used as
predictors in a linear mixedmodel of FEV1 %
predicted, as well as logistic regression
models of both moderate-to-severe and
severe COPD incorporating generalized
estimating equations. Models were
controlled for age, pack-years of smoking,
principal components of genetic ancestry,
and for familial correlation. In addition, we
used the pROC (40) and GenABEL (41)
packages in R to compare the accuracy of
two models (i.e., model with genetic risk
factors and clinical predictors versus the
clinical predictors alone) through receiver
operator characteristic curves and net
reclassification index (NRI). Subjects were
divided into three tiers of COPD risk (low,
0–33.3%; intermediate, 33.4–66.7%; and
high, 66.8–100%) for NRI analysis to assess
the discriminatory benefit of adding genetic
information to the clinical risk model of age
and pack-years of smoking alone.
Additional details regarding the SNPs
and cohorts used in this study—genotype-,
marker-, and subject-level quality
control, and risk score modeling and NRI
analysis—are available in the MATERIALS AND
METHODS section and the online supplement.
Results
The baseline characteristics of all cohorts are
shown in Table 1. Notably, the TCGS-
Korea, TCGS-Poland, and NETT/NAS
studies were designed to contain only
severe COPD cases, which is reflected in the
low average FEV1 % predicted seen among
cases for these studies.
Genetic Association Analysis
The moderate-to-severe COPD analysis
included 9,221 cases and 7,486 control
subjects, and confirmed signals in the
previously described TGFB2, FAM13A,
HHIP, CHRNA3/CHRNA5/IREB2, and
RIN3 regions; in addition, an SNP in
16p11.2, recently described in an exome
chip analysis of these same cohorts (42),
was associated with moderate-to-severe
COPD (rs40834, P = 1.903 1028, estimated
odds ratio [OR] = 1.17; Table E2). The
analysis of severe COPD (Table 2) included
5,300 cases and 7,486 control subjects.
We confirmed significance of SNPs in the
TGFB2, FAM13A, HHIP, MMP3/MMP12,
and CHRNA3/CHRNA5/IREB2 regions.
We also identified two SNPs at loci not
previously described as genome-wide
significant: 5q23.2 between the PRDM6 and
PPIC genes (rs6860095, P = 1.013 1028,
estimated OR= 1.24), and an intronic
SNP within the PPP4R4 gene (rs112458284,
P = 1.283 1028, estimated OR= 1.69) in
14q32.13.
We examined these loci using the GTEx
expression quantitative trait loci database (43)
and Haploreg v4.1 (44). SNP rs6860095
affected gene expression levels of PPIC, snoU13,
SNX2, and RN7SL689P in multiple tissues,
although not in lung tissue. No significant
expression quantitative trait loci were
found for SNP rs112458284; however, it lies
approximately 200 kb away from SERPINA1,
which encodes the protein responsible for
alpha-1 antitrypsin deficiency (45, 46).
We investigated whether rs112458284
could be tagging alleles of SERPINA1 known
to contribute to risk of COPD (e.g., the Z
allele, rs28929474, or S-allele, rs17580).
rs112458284 showed linkage disequilibrium
(LD) with the Z allele in directly genotyped
(i.e., not imputed) samples from
COPDGene non-Hispanic white subjects
(r2 = 0.41, normalized coefficient of linkage
disequilibrium [D9] = 0.78) and, to a lesser
extent, the S allele (r2 = 8.633 1025, D9 =
0.25). Consistent with this hypothesis, the Z
allele was associated with COPD at
near–genome-wide significance in our
primary analysis using imputed data in
COPDGene (P = 1.533 1027, OR = 1.78,
confidence interval [CI] = 1.44–2.21);
Table 2. Genome-Wide Significant Severe Chronic Obstructive Pulmonary Disease Associations
rs ID Chromosome
Base
Position Effect Allele P Value OR (95% CI)
Effect Allele
Frequency Nearest Gene(s)
rs1890995 1 218604678 A 3.793 10211 1.27 (1.37–1.19) 0.73 TGFB2
rs4416442 4 89866713 T 5.383 10217 1.32 (1.39–1.23) 0.43 FAM13A
rs13141641 4 145506456 T 1.693 10221 1.38 (1.29–1.48) 0.61 HHIP
rs6860095 5 122405957 A 1.013 1028 1.24 (1.15–1.33) 0.74 PRDM6/PPIC
rs679620 11 102713620 T 1.873 1028 1.19 (1.12–1.27) 0.54 MMP3/MMP12
rs112458284 14 94672731 T 1.283 1028 1.69 (2.04–1.41) 0.04 PPP4R4
rs17486278 15 78867482 A 1.703 10227 1.43 (1.54–1.35) 0.37 CHRNA5
Definition of abbreviations: CI, confidence interval; OR, odds ratio.
Significant associations for Global Initiative for Chronic Obstructive Lung Disease spirometric stages III–IV chronic obstructive pulmonary disease (COPD),
organized by chromosome. In each case, the lead single-nucleotide polymorphism for the locus is presented. Effect alleles represent the allele that is
associated with the stated odds ratio for COPD-risk. Base position was calculated using human genome assembly 19 (hg19) coordinates.
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this signal improved using genotyping
data (P = 2.053 1028, OR = 1.84, CI =
1.49–2.27), although rs112458284 was still
the strongest association signal in the
region. To further investigate whether
there was any association signal at the
rs112458284 that was independent from the
Z allele, we also conditioned on the Z allele
in a meta-analysis model, and found that
the association signal for rs112458284 was
attenuated (P = 0.0087).
Known alpha-1 antitrypsin deficiency
was an exclusion criterion in our study;
however, our genotyping (and imputed
data) identified three previously
unrecognized Z allele homozygotes in the
Poland cohort (35) and six additional
Z allele homozygotes in the ECLIPSE
cohort (47). After removing these subjects,
the rs112458284 association was only
mildly attenuated (P = 7.223 1028), as was
the association with the Z allele (P = 9.293
1028, OR = 1.80, CI = 1.45–2.23). Thus,
heterozygous carriers of the Z allele appear
to be driving a large proportion of the
association, consistent with prior studies
showing an increased risk of COPD
for MZ heterozygotes (48). In addition,
these results suggest that if we had not
specifically excluded subjects with known
alpha-1 antitrypsin deficiency in our other
populations, the association with SNP
rs112458284 would likely be even more
extreme (49). Allele frequencies for the Z allele
in each cohort are provided in Table E3. The
poor imputation quality of the S allele in
our cohorts prevented us from further assessing
its impact on the rs112458284 association.
We next examined our other SNPs at
a more liberal P value threshold. Using a
Bonferroni significance threshold for 3,346
SNPs (P, 1.493 1025), we identified
suggestive associations at three loci
(THSD4, AGER/PPT2, and ADAM19).
All of these were in regions previously
associated in GWASs of lung function.
We then examined linkage disequilibrium
within each candidate locus to further
explore whether these associations
represented the same variants as previous
associations. We defined “lead SNP” as the
association yielding the lowest P value in a
given region, and the “candidate SNP” as
the previously described variant. In 14 of
these lead SNPs, LD with the candidate
SNP measured by D9 was greater than 0.8,
whereas eight also had an r2 greater than
0.3 (Table 3). Notably, SNPs associated
with lower lung function showed a
directionally consistent increased risk
for COPD in 23 of 25 previously reported
SNPs directly genotyped in our meta-
analysis (binomial for enrichment,
P = 9.73 1026). These 23 lung function
risk alleles included 12 showing a
nominally statistically significant (P, 0.05)
effect on COPD risk (see Table 3). Only
lung function risk alleles in the ZKSCAN3
and NCR3-AIF1 genes showed a
directionally discordant effect on COPD
susceptibility (lower risk of COPD),
although these discordant association
results were not statistically significant.
Additional results for other variants are
reported in Table E4.
Genetic Risk Scores
We next examined the ability of genetic risk
scores to explain both FEV1 % predicted
and COPD affection status. Based on
our results presented previously here, we
constructed risk scores using genome-wide
significant SNPs associated with COPD
(COPD7 score, comprised of seven COPD
risk SNPs) and also including genome-wide
significant SNPs associated with lung
function in population-based studies
(LUNG30 score, composed of thirty lung
function associated risk SNPs); Tables 4
and E5 describe the loci involved in each
score. We evaluated the risk scores using
the ICGN cohort, the largest available
cohort not used in the discovery of these
risk loci. Results from the unadjusted model
are shown in Figure 1. In a linear mixed
model, adjusting for age, pack-years of
smoking, principal components of ancestry,
and a within-family component, we found
the COPD7 risk score (ranging from 0 to 14
scoring alleles) was associated with a 1.86%
reduction in FEV1 % predicted for each
additional risk allele carried (Table 5).
Using generalized estimating equations for
models of moderate-to-severe and severe
COPD (Table 6), each additional risk allele
in the COPD7 risk score was associated
with an OR of 1.18 for moderate-to-severe
COPD and 1.19 for severe COPD
(P = 4.13 1028 and P = 4.43 1028,
respectively). We found nearly identical
results for a standard logistic regression
(OR = 1.17 and OR = 1.19, respectively)
without family adjustment, and therefore
used these simpler models to generate
receiver operator characteristic curves for
affection status using genetic variants alone,
age and pack-years, and the combination of
age, pack-years, and genetic information.
The area under the curve (AUC) for the
genetic model was 0.58 for moderate-to-
severe COPD and 0.59 for severe COPD.
In addition, adding genetic risk scores
(COPD7) only modestly increased the AUC
(Figure 2) over the AUC of the clinical
model. Three-tiered categorical analysis
of reclassification (50) after addition of
the COPD7 risk score and adjustment for
genetic components of ancestry into the
clinical model (containing only age and
pack-years of smoking) resulted in an
NRI of 0.053 (P = 2.323 1023) for the
combined model risk stratification of
Table 4. Genetic Risk Score Loci
Gene SNP Identifier
CHRNA3 rs12914385
RAB4B/EGLN2/
MIA/CYP2A6
rs7937
RIN3 rs754388
TGFB2 rs4846480
MMP12 rs626750
HHIP rs13141641
FAM13A rs4416442
PTCH1 rs16909898
C10orf11 rs11001819
HTR4 rs11168048
DNER rs7594321
HDAC4-FLJ43879 rs12477314
MFAP2 rs2284746
ARMC2 rs2798641
LRP1 rs11172113
RARB rs1529672
GSTCD/INTS12/NPNT rs10516526
NCR3-AIF1 rs2857595
MECOM/EVI1 rs1344555
AGER/PPT2 rs2070600
ZKSCAN3 rs6903823
SPATA9-RHOBTB3 rs153916
MMP15 rs12447804
HLA-DQB1 rs7765379
KCNJ2/CASC17 rs11654749
GPR126 rs3817928
TGFB2-LYPLAL1 rs993925
CDC123 rs7068966
KCNE2-LINC00310/
C21orf82
rs9978142
THSD4 rs12899618
Definition of abbreviations: COPD7, genetic risk
score composed of seven COPD risk SNPs
(ranging from 0 to 14 scoring alleles); LUNG30,
genetic risk score compsed of thirty lung
function associated risk SNPs (ranging from 0 to
60 scoring alleles); SNP, single-nucleotide
polymorphism.
Genetic risk scores were composed using
previous chronic obstructive pulmonary disease
(COPD) and lung function–associated loci. The
LUNG30 score included all of the loci listed in the
above table; the COPD7 score included only
those in the bold. Loci names are based on
previously reported SNP associations annotated
to the nearest gene or region.
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moderate-to-severe COPD, and an NRI
of 0.047 for risk stratification of severe
COPD (P = 0.01). For the expanded
LUNG30 score, we found a lower per-allele
effect, but larger overall effect, because
more factors went into the score (Tables 5
and 6). We also tested risk scores in the
TCGS-Poland and COPDGene cohorts and
found comparable results (see MATERIALS
AND METHODS and the online supplement).
Discussion
Genetic association studies in COPD have
identified well replicated genome-wide
associations with COPD, but the majority of
genetic susceptibility remains unexplained.
In a large-scale genetic association meta-
analysis of nine cohorts, analyzing both
moderate-to-severe and severe COPD,
we identified two new associations at
genome-wide significance with severe
COPD, including one in strong LD with
SERPINA1, and associations at a more
liberal significance threshold in regions
previously associated with population-
based lung function. We found consistent
directions of effect on risk to COPD in
23 previously identified markers associated
with lung function, consistent with recent
reports (7). We also constructed genetic
risk scores that showed compelling
relationships for quantitative measures of
lung function and modest discrimination
for COPD affection status. Our results
further inform the discussion of how
genetic variants could influence COPD
susceptibility.
The discovery that variants in LD
with SERPINA1 are associated with
severe COPD demonstrates how genetic
association studies can confirm known
disease mechanisms. This rs112458284
variant is also in strong LD with
rs45505795 near SERPINA10 (r2 = 0.96 and
D9 = 1.0) in 1,000 Genomes EUR Phase I
v3 data (www.internationalgenome.org),
which we recently described in a GWAS of
quantitative measures of emphysema (47).
The 5q23.2 region containing SNP
rs6860095 is strongly associated with
severe COPD risk. Both PPIC and PRDM6
lie in this region. PPIC (also known as
cyclophilin C) has functions related to
mitochondrial metabolism, inflammation,
and immune response through its
interactions with cyclosporine A. Although
the related protein, cyclophilin A, has been
associated with both COPD (51) and lung
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Figure 1. Unadjusted FEV1% predicted by number of COPD7 and LUNG30 risk alleles. Boxplots showing FEV1 % predicted stratified by number of risk
alleles in the International COPD Genetics Network pedigree-based cohort. For each boxplot, the black line represents the median data point, the upper
and lower edges of the light blue box represent data within the 25th to 75th percentile of the distribution, the upper and lower “whiskers” represent the
upper and lower limits of the data, and open circles represent outliers. The figure on the left shows the COPD7 risk score, whereas the figure on the right
shows the LUNG30 risk score. COPD7, genetic risk score composed of seven COPD risk SNPs (ranging from 0 to 14 scoring alleles); LUNG30, genetic
risk score compsed of thirty lung function associated risk SNPs (ranging from 0 to 60 scoring alleles); SNP, single-nucleotide polymorphism.
Table 5. Genetic Risk Scores: Lung Function in International Chronic Obstructive
Pulmonary Disease Genetics Network
Risk
Score
Unadjusted FEV1 %
per Risk Allele
(95% CI) P Value
Adjusted FEV1 %
per Risk Allele
(95% CI) P Value
COPD7 22.02 (21.34 to 22.70) 6.743 1029 21.86 (21.24 to 22.50) 7.903 1029
LUNG30 21.18 (20.83 to 21.53) 4.703 10211 21.10 (20.78 to 21.43) 3.783 10211
Definition of abbreviations: CI, confidence interval; COPD7, genetic risk score composed of seven
COPD risk SNPs (ranging from 0 to 14 scoring alleles); LUNG30, genetic risk score composed of
thirty lung function associated risk SNPs (ranging from 0 to 60 scoring alleles); SNP, single-nucleotide
polymorphism.
For each risk score (chronic obstructive pulmonary disease [COPD] 7 and LUNG30), the linear
mixed-model coefficient is presented with 95% CI and P value. Final model included adjustment for
age, pack-years, familial correlation, and principal components for genetic ancestry, whereas the
unadjusted model was not adjusted for age and pack-years.
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cancer (52), to our knowledge, no prior
study has shown significant association
between PPIC and risk of COPD. The
PRDI-BF1 and RIZ homology domain
containing 6 (PRDM6) protein is involved
in chromatin remodeling and transcriptional
control of smooth muscle gene expression
(53). Expression of PRDM6 has been
implicated in the pseudoglandular and
canalicular stages of lung morphogenesis in
murine models, and expression has been
documented in smooth muscle of the
developing murine trachea, bronchi,
and pulmonary trunk (53). Additional studies
are needed to confirm association between
markers in 5q23.2 and severe COPD.
We examined genomic loci previously
associated with FEV1, FEV1/FVC, and
Table 6. Genetic Risk Scores: Affection Status in International Chronic Obstructive Pulmonary Disease Genetics Network
Moderate COPD P Value Severe COPD P Value
COPD7
OR per risk allele (95% CI) 1.18 (1.11–1.25) 4.103 1028 1.19 (1.12–1.27) 4.433 1028
AUC (95% CI) 0.58 (0.56–0.61) 0.59 (0.56–0.61)
Total NRI (95% CI) 0.053 (0.019–0.086) 2.323 1023 0.047 (0.01–0.084) 1.323 1022
Event NRI, % 0.23 0.83
Nonevent NRI, % 5.03 3.88
LUNG30
OR per risk allele (95% CI) 1.12 (1.09–1.15) 1.253 10213 1.12 (1.09–1.15) 1.253 10213
AUC (95% CI) 0.60 (0.57–0.62) 0.60 (0.57–0.63)
NRI (95% CI) 0.090 (0.053–0.126) 1.723 1026 0.047 (0.007–0.087) 2.223 1022
Event NRI, % 2.35 0.65
Nonevent NRI, % 6.61 4.67
Definition of abbreviations: AUC, area under the curve; CI, confidence interval; COPD, chronic obstructive pulmonary disease; COPD7, genetic risk score
composed of seven COPD risk SNPs (ranging from 0 to 14 scoring alleles); LUNG30, genetic risk score composed of thirty lung function associated risk
SNPs (ranging from 0 to 60 scoring alleles); NRI, net reclassification index; OR, odds ratio; SNP, single-nucleotide polymorphism.
For each risk score (COPD7 and LUNG30), OR is for each additional risk allele on the outcome of either moderate COPD (GOLD [Global Initiative for
Chronic Obstructive Lung Disease] II–IV) or severe COPD (GOLD III–IV). AUC is for a model including only the genetic data of risk score alleles adjusted for
principal components of genetic ancestry. NRI represents the three-tiered value of the model combining genetic risk score, age, pack-years of smoking,
and principal components of genetic ancestry compared to the model containing age and pack-years alone. Event NRI represents the percentage of
subjects with the outcome of COPD correctly reclassified to a higher risk group after adding genetic data. Nonevent NRI represents the percentage of
subjects without the outcome of COPD correctly reclassified to a lower risk group after adding genetic data.
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Figure 2. Severe COPD diagnosis using COPD7 and LUNG30. Receiver operator characteristic curves showing diagnostic accuracy of models based on
clinical variables (age and pack-years of smoking alone, shown in light blue), COPD7 or LUNG30 risk allele data alone (green), and the combination
of clinical and genetic risk score data (dark blue) for predicting Global Initiative for Chronic Obstructive Lung Disease spirometric stages III–IV COPD
affection status in the International COPD Genetics Network cohort. The differences between the clinical and combined curves were statistically significant
in both the COPD7 (difference 0.010; P = 4.43 1023) and the LUNG30 scores (difference 0.012; P = 4.73 1023).
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additional variants previously hypothesized
to be associated with COPD (19). SNPs that
met criteria for suggestive association were
found in regions previously associated with
lung function, including the AGER/PPT2
and the THSD4 regions. In addition, the
majority of variants associated with
quantitative measures of lung function
showed consistent directions of effect for
both COPD and low lung function.
Genetic risk scores using selected risk
variants from COPD-based cohorts could
provide a clinically relevant context to
individual-level genetic data, and could
have applications in assessing risk to COPD
and its severity (25). We investigated the
ability of genetic risk scores to explain
COPD risk and FEV1 % predicted. Genetic
data alone only achieved an AUC of
approximately 0.6 in our modeling of
moderate-to-severe COPD risk. This
finding is comparable to the AUC of
genetic risk scores in other complex
diseases, such as coronary artery disease (54)
and type II diabetes (55). This low AUC of
our risk score may be due to the fact that
genetic data do not account for the
contributions to COPD of other significant
risk factors, such as age and environmental
exposures, such as pack-years of smoking.
The addition of genetic data to the clinical
model including age and pack-years of
smoking resulted in statistically significant,
but small, increases in AUCs and in
statistically significant NRI values when
classifying risk for severe COPD.
Interpretation of the NRI is more
straightforward for clinically actionable
consensus endpoints, such as primary
prevention statin therapy for coronary
artery disease outcomes, which are less
well defined for COPD. Despite these
concerns, the clinical relevance of this
model is most apparent in the risk score
coefficient itself. The LUNG30 model implies
that a subject with 35 risk alleles would show a
threefold increase in risk of COPD compared
with a subject with a score of 25, all other
variables being equal.
Similarly, in our modeling of FEV1 %
predicted, we found a small, but detectable,
effect of each individual risk allele, although
the cumulative effect of this score may be
clinically relevant. For example, within the
ICGN dataset, we had subjects with as few as
16 and as many as 45 alleles in their LUNG30
score. Based on our model, this difference in
alleles would account for an approximately
30% difference in FEV1 % predicted, holding
all other variables equal. Such a 30% FEV1 %
predicted difference implies that two people
(with similar age and pack-years of smoking)
may fall into different GOLD severity classes
due to the effect of these risk alleles alone.
Although the COPD-based ascertainment of
the ICGN pedigrees may have led to
enrichment of these risk alleles in this cohort,
the significance of the risk scores was robust
when tested in two additional case–control
cohorts.
Despite having analyzed over 16,000
subjects, our study and the experience in
other GWAS suggest that power is still a
major limitation in detecting additional
COPD associations. The definition of
COPD phenotypes and its severity by
spirometric criteria alone (2) was consistent
in our meta-analysis; however, this does not
address other aspects of heterogeneity in
COPD that may be under genetic control
(such as emphysema or exacerbations). The
study was cross-sectional in design, with
lung function assessment at only one point
of time, so we cannot assess the impact
of lung function trajectories (56) in
our models. This study was not a
comprehensive survey of genome-wide
data, and its ability to detect new
associations was limited to previously
identified loci and their surrounding
regions. Four of the datasets in our meta-
analysis were previously investigated for
genetic associations for COPD status (18),
so our results are enriched for previously
discovered associations. In addition,
genotyping was performed before the
results of recent COPD and lung function
GWAS studies by the UK BiLEVE group
(7) and Soler Artigas and colleagues (57,
58) were published, and the additional risk
loci for COPD and lung function found in
these studies were not included in our
analysis. We chose to use a simple model
for our genetic (and clinical) risk scores.
More sophisticated models using these
SNPs, based on genome-wide results, and
incorporating additional clinical factors,
may result in improved prediction. In
pathway analysis in Gene Ontology,
Kyoto Encyclopedia of Genes and
Genomes, and the Reactome (see the
supplemental MATERIALS AND METHODS and
RESULTS sections), the closest gene(s) to
the LUNG30 risk score variants showed
enrichment in gene sets related to structural
components of lung development, control
of lung development, inflammatory response,
and response to steroid hormone, among
others. These enriched terms and pathways
may help to provide insight into the
pathophysiologic mechanisms of COPD
pathogenesis that are represented by the
LUNG30 association signal. However, our
risk scores focused on SNPs previously
associated with lung function and COPD;
most of the causal genes at these loci are
not known, and these signals capture
only a minority of relevant genetic
mechanisms contributing to COPD
pathogenesis. The performance of our
genetic risk scores in other racial groups
and in never-smokers has not been tested,
although this is an area of interest for follow-
up investigations. Although associations with
SNPs rs112458284 and rs6860095 did achieve
genome-wide levels of significance in our
analysis of severe COPD, these results still
need to be replicated in independent
populations.
In summary, we performed a meta-
analysis of markers in selected genes,
and discovered two new SNPs associated
with severe COPD that reached significance
levels equivalent to accepted thresholds
of genome-wide significance, one of
which tags recognized risk alleles in
SERPINA1. Our study is one of the
largest genetic association studies of severe
COPD, and the first to identify SERPINA1
at genome-wide significance for COPD.
Our study supports the idea that loci
associated with lung function play some
role in susceptibility to COPD. We also
showed the clinical applicability of
simple genetic risk scores for explaining
COPD spirometric severity in an
independent cohort. This study adds to
the growing body of genetic knowledge
about COPD, including efforts at
subtyping, prediction, and mechanistic
investigation, which may ultimately inform
patient counseling, clinical decision-
making, and lead to new therapies for
this disease. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
Acknowledgments: The authors acknowledge
and thank Augustine M. K. Choi, M.D. (Weill
Cornell Medicine, New York, NY), for his support
of this project. In addition, they thank the
following members of the individual study
cohorts, without whom this work would not have
been possible.
The COPDGene Investigators
Are: Administrative Core: James Crapo, M.D.
(Principal Investigator), Edwin Silverman, M.D.,
ORIGINAL RESEARCH
Busch, Hobbs, Zhou, et al.: Genetic Association and Risk Scores in COPD 43
Ph.D. (Principal Investigator), Barry Make, M.D.,
Elizabeth Regan, M.D., Ph.D.
Genetic Analysis Core: Terri Beaty, Ph.D., Nan
Laird, Ph.D., Christoph Lange, Ph.D., Michael
Cho, M.D., Stephanie Santorico, Ph.D., John
Hokanson, M.P.H., Ph.D., Dawn DeMeo, M.D.,
M.P.H., Nadia Hansel, M.D., M.P.H., Craig
Hersh, M.D., M.P.H., Peter Castaldi, M.D.,
M.Sc., Merry-Lynn McDonald, Ph.D., Emily Wan,
M.D., Megan Hardin, M.D., Jacqueline
Hetmanski, M.S., Margaret Parker, M.S., Marilyn
Foreman, M.D., Brian Hobbs, M.D., Robert
Busch, M.D., Adel El-Bouiez, M.D., Dandi Qiao,
Ph.D., Elizabeth Regan, M.D., Eitan Halper-
Stromberg, Ph.D., Ferdouse Begum, Ph.D.,
Sungho Won, Ph.D., Sharon Lutz, Ph.D.
Imaging Core: David A. Lynch, M.B., Harvey O.
Coxson, Ph.D., MeiLan K. Han, M.D., M.S., Eric
A. Hoffman, Ph.D., Stephen Humphries, M.S.,
Francine L. Jacobson, M.D., Philip F. Judy, Ph.D.,
Ella A. Kazerooni, M.D., John D. Newell, Jr.,
M.D., Elizabeth Regan, M.D., James C. Ross,
Ph.D., Raul San Jose Estepar, Ph.D., Berend C.
Stoel, Ph.D., Juerg Tschirren, Ph.D., Eva van
Rikxoort, Ph.D., Bram van Ginneken, Ph.D.,
George Washko, M.D., Carla G. Wilson, M.S.,
Mustafa Al Qaisi, M.D., Teresa Gray, Alex
Kluiber, Tanya Mann, Jered Sieren, Douglas
Stinson, Joyce Schroeder, M.D., Edwin Van
Beek, M.D., Ph.D.
Pulmonary Function Test Quality Assurance
Core, Salt Lake City, UT: Robert Jensen, Ph.D.
Data Coordinating Center and Biostatistics,
National Jewish Health, Denver, CO: Douglas
Everett, Ph.D., Anna Faino, M.S., Matt Strand,
Ph.D., Carla Wilson, M.S.
Epidemiology Core, University of Colorado
Anschutz Medical Campus, Aurora, CO: John E.
Hokanson, M.P.H., Ph.D., Gregory Kinney, M.P.H.,
Ph.D., Sharon Lutz, Ph.D., Kendra Young Ph.D.,
Katherine Pratte, M.S.P.H., Lindsey Duca, M.S.
Ann Arbor Veterans Administration (VA), Ann
Arbor, MI: Jeffrey L. Curtis, M.D., Carlos H.
Martinez, M.D., M.P.H., Perry G. Pernicano, M.D.
Baylor College of Medicine, Houston, TX: Nicola
Hanania, M.D., M.S., Philip Alapat, M.D.,
Venkata Bandi, M.D., Mustafa Atik, M.D., Aladin
Boriek, Ph.D., Kalpatha Guntupalli, M.D.,
Elizabeth Guy, M.D., Amit Parulekar, M.D.,
Arun Nachiappan, M.D.
Brigham and Women’s Hospital, Boston, MA:
Dawn DeMeo, M.D., M.P.H., Craig Hersh, M.D.,
M.P.H., George Washko, M.D., Francine
Jacobson, M.D., M.P.H.
Columbia University, New York, NY: R. Graham
Barr, M.D., Dr.P.H., Byron Thomashow, M.D.,
John Austin, M.D., Belinda D’Souza, M.D.,
Gregory D. N. Pearson, M.D., Anna
Rozenshtein, M.D., M.P.H.
Duke University Medical Center, Durham, NC:
Neil MacIntyre, Jr., M.D., Lacey Washington,
M.D., H. Page McAdams, M.D.
Health Partners Research Foundation,
Minneapolis, MN: Charlene McEvoy, M.D.,
M.P.H., Joseph Tashjian, M.D.
Johns Hopkins University, Baltimore, MD:
Robert Wise, M.D., Nadia Hansel, M.D.,
M.P.H., Robert Brown, M.D., Karen Horton, M.D.,
Nirupama Putcha, M.D., M.H.S.
Los Angeles Biomedical Research Institute at
Harbor University of California Los Angeles
Medical Center, Torrance, CA: Richard
Casaburi, Ph.D., M.D., Alessandra Adami,
Ph.D., Janos Porszasz, M.D., Ph.D., Hans
Fischer, M.D., Ph.D., Matthew Budoff, M.D.,
Harry Rossiter, Ph.D.
Michael E. DeBakey VAMC, Houston, TX: Amir
Sharafkhaneh, M.D., Ph.D., Charlie Lan, D.O.
Minneapolis VA, Minneapolis, MN: Christine
Wendt, M.D., Brian Bell, M.D.
Morehouse School of Medicine, Atlanta, GA:
Marilyn Foreman, M.D., M.S., Gloria Westney,
M.D., M.S., Eugene Berkowitz, M.D., Ph.D.
National Jewish Health, Denver, CO: Russell
Bowler, M.D., Ph.D., David Lynch, M.D.
Reliant Medical Group, Worcester, MA: Richard
Rosiello, M.D., David Pace, M.D.
Temple University, Philadelphia, PA: Gerard
Criner, M.D., David Ciccolella, M.D., Francis
Cordova, M.D., Chandra Dass, M.D.,
Gilbert D’Alonzo, D.O., Parag Desai, M.D.,
Michael Jacobs, Pharm.D., Steven Kelsen, M.D.,
Ph.D., Victor Kim, M.D., A. James Mamary,
M.D., Nathaniel Marchetti, D.O., Aditi Satti, M.D.,
Kartik Shenoy, M.D., Robert M. Steiner, M.D.,
Alex Swift, M.D., Irene Swift, M.D., Maria Elena
Vega-Sanchez, M.D.
University of Alabama, Birmingham, AL: Mark
Dransfield, M.D., William Bailey, M.D., J.
Michael Wells, M.D., Surya Bhatt, M.D., Hrudaya
Nath, M.D.
University of California, San Diego, CA: Joe
Ramsdell, M.D., Paul Friedman, M.D., Xavier
Soler, M.D., Ph.D., Andrew Yen, M.D.
University of Iowa, Iowa City, IA: Alejandro
Comellas, M.D., John Newell, Jr., M.D., Brad
Thompson, M.D.
University of Michigan, Ann Arbor, MI: MeiLan
Han, M.D., Ella Kazerooni, M.D., Carlos
Martinez, M.D.
University of Minnesota, Minneapolis, MN:
Joanne Billings, M.D., Tadashi Allen, M.D.
University of Pittsburgh, Pittsburgh, PA: Frank
Sciurba, M.D., Divay Chandra, M.D., M.Sc.,
Joel Weissfeld, M.D., M.P.H., Carl Fuhrman,
M.D., Jessica Bon, M.D.
University of Texas Health Science Center at San
Antonio, San Antonio, TX: Antonio Anzueto,
M.D., Sandra Adams, M.D., Diego Maselli-
Caceres, M.D., Mario E. Ruiz, M.D.
The International COPD Genetics Network
Investigators Are: Edwin K. Silverman,
Brigham & Women’s Hospital, Boston, MA;
David A. Lomas, Cambridge Institute for
Medical Research, University of Cambridge,
Cambridge, UK; Barry J. Make, National Jewish
Medical and Research Center, Denver, CO;
Alvar Agusti and Jaume Sauleda, Hospital
Universitari Son Dureta, Fundacio´n Caubet-
Cimera and Ciber Enfermedades Respiratorias,
Islas Baleares and Palma de Mallorca, Spain;
Peter M. A. Calverley, University of Liverpool,
Liverpool, UK; Claudio F. Donner, Division of
Pulmonary Disease, S. Maugeri Foundation,
Veruno (NO), Italy; Robert D. Levy, University of
British Columbia, Vancouver, BC, Canada;
Peter D. Pare´, University of British Columbia,
Vancouver, BC, Canada; Stephen Rennard,
Section of Pulmonary & Critical Care, University
of Nebraska Medical Center, Omaha, NE;
Jørgen Vestbo, Department of Cardiology and
Respiratory Medicine, Hvidovre Hospital,
Copenhagen, Denmark.
Principal Investigators and Centers
Participating in Evaluation of COPD
Longitudinally to Identify Predictive
Surrogate End-Points (ECLIPSE;
NCT00292552, SC0104960) Include: Bulgaria:
Y. Ivanov, Pleven; K. Kostov, Sofia. Canada:
J. Bourbeau, Montreal, PQ; M. Fitzgerald,
Vancouver, BC; P. Hernandez, Halifax, NS;
K. Killian, Hamilton, ON; R. Levy, Vancouver,
BC; F. Maltais, Montreal, PQ; D. O’Donnell,
Kingston, ON. Czech Republic: J. Krepelka,
Prague. Denmark: J. Vestbo, Hvidovre. the
Netherlands: E. Wouters, Horn-Maastricht.
New Zealand: D. Quinn, Wellington. Norway:
P. Bakke, Bergen. Slovenia: M. Kosnik,
Golnik. Spain: A. Agusti, J. Sauleda, P. de
Mallorca. Ukraine: Y. Feschenko, V. Gavrisyuk,
L. Yashina, Kiev; N. Monogarova, Donetsk.
United Kingdom: P. Calverley, Liverpool;
D. Lomas, Cambridge; W. MacNee, Edinburgh;
D. Singh, Manchester; J. Wedzicha, London.
United States: A. Anzueto, San Antonio, TX;
S. Braman, Providence, RI; R. Casaburi, Torrance,
CA; B. Celli, Boston, MA; G. Giessel, Richmond,
VA; M. Gotfried, Phoenix, AZ; G. Greenwald,
Rancho Mirage, CA; N. Hanania, Houston, TX;
D. Mahler, Lebanon, NH; B. Make, Denver, CO;
S. Rennard, Omaha, NE; C. Rochester, New
Haven, CT; P. Scanlon, Rochester, MN;
D. Schuller, Omaha, NE; F. Sciurba, Pittsburgh,
PA; A. Sharafkhaneh, Houston, TX; T. Siler,
St. Charles, MO; E. Silverman, Boston, MA;
A. Wanner, Miami, FL; R. Wise, Baltimore,
MD; R. ZuWallack, Hartford, CT.
ECLIPSE Steering Committee: H. Coxson
(Canada), C. Crim (GlaxoSmithKline, USA), L.
Edwards (GlaxoSmithKline, USA), D. Lomas (UK),
W. MacNee (UK), E. Silverman (USA), R. Tal
Singer (Co-chair, GlaxoSmithKline, USA),
J. Vestbo (Co-chair, Denmark), J. Yates
(GlaxoSmithKline, USA).
ECLIPSE Scientific Committee: A. Agusti
(Spain), P. Calverley (UK), B. Celli (USA),
C. Crim (GlaxoSmithKline, USA), B. Miller
(GlaxoSmithKline, USA), W.MacNee (Chair, UK), S.
Rennard (USA), R. Tal-Singer (GlaxoSmithKline,
USA), E. Wouters (the Netherlands), J. Yates
(GlaxoSmithKline, USA).
Coinvestigators in the National Emphysema
Treatment Trial Genetics Ancillary Study
also Include: J. Benditt, G. Criner, M. DeCamp,
P. Diaz, M. Ginsburg, L. Kaiser, M. Katz,
M. Krasna, N. MacIntyre, R. McKenna,
F. Martinez, Z. Mosenifar, J. Reilly, A. Ries,
P. Scanlon, F. Sciurba, and J. Utz.
ORIGINAL RESEARCH
44 American Journal of Respiratory Cell and Molecular Biology Volume 57 Number 1 | July 2017
References
1. Kochanek KD, Murphy SL, Xu J. Deaths: final data for 2011. Natl Vital
Stat Rep 2015;63:1–120.
2. Vestbo J, Hurd SS, Agustı´ AG, Jones PW, Vogelmeier C, Anzueto A,
Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy
for the diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit Care
Med 2013;187:347–365.
3. Ingebrigtsen T, Thomsen SF, Vestbo J, van der Sluis S, Kyvik KO,
Silverman EK, Svartengren M, Backer V. Genetic influences on
chronic obstructive pulmonary disease—a twin study. Respir Med
2010;104:1890–1895.
4. McCloskey SC, Patel BD, Hinchliffe SJ, Reid ED, Wareham NJ, Lomas
DA. Siblings of patients with severe chronic obstructive pulmonary
disease have a significant risk of airflow obstruction. Am J Respir Crit
Care Med 2001;164:1419–1424.
5. Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell
EJ, O’Donnell WJ, Reilly JJ, Ginns L, Mentzer S, et al. Genetic
epidemiology of severe, early-onset chronic obstructive pulmonary
disease: risk to relatives for airflow obstruction and chronic bronchitis.
Am J Respir Crit Care Med 1998;157:1770–1778.
6. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative
relationships between cigarette smoking and ventilatory function. Am
Rev Respir Dis 1977;115:195–205.
7. Wain LV, Shrine N, Miller S, Jackson VE, Ntalla I, Soler Artigas M,
Billington CK, Kheirallah AK, Allen R, Cook JP, et al.; UK Brain
Expression Consortium (UKBEC); OxGSK Consortium. Novel insights
into the genetics of smoking behaviour, lung function, and chronic
obstructive pulmonary disease (UK BiLEVE): a genetic association
study in UK Biobank. Lancet Respir Med 2015;3:769–781.
8. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL,
Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, et al.; ICGN
Investigators; ECLIPSE Investigators; COPDGene Investigators. A
genome-wide association study of COPD identifies a susceptibility
locus on chromosome 19q13. Hum Mol Genet 2012;21:947–957.
9. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP,
Bakke P, Gulsvik A, et al.; ICGN Investigators. A genome-wide association
study in chronic obstructive pulmonary disease (COPD): identification of
two major susceptibility loci. PLoS Genet 2009;5:e1000421.
10. DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, Litonjua A,
Bueno R, Pillai SG, Lomas DA, Sparrow D, et al. Integration of
genomic and genetic approaches implicates IREB2 as a
COPD susceptibility gene. Am J Hum Genet 2009;85:493–502.
11. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP,
DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, et al. Variants
in FAM13A are associated with chronic obstructive pulmonary
disease. Nat Genet 2010;42:200–202.
12. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, Klemm A,
Flicek P, Manolio T, Hindorff L, et al. The NHGRI GWAS catalog, a
curated resource of SNP-trait associations. Nucleic Acids Res 2014;
42:D1001–D1006.
13. Zhou JJ, Cho MH, Castaldi PJ, Hersh CP, Silverman EK, Laird NM.
Heritability of chronic obstructive pulmonary disease and related
phenotypes in smokers. Am J Respir Crit Care Med 2013;188:
941–947.
14. Chakravarti A, Clark AG, Mootha VK. Distilling pathophysiology from
complex disease genetics. Cell 2013;155:21–26.
15. Corvol H, Hodges CA, Drumm ML, Guillot L. Moving beyond genetics:
is FAM13A a major biological contributor in lung physiology and
chronic lung diseases? J Med Genet 2014;51:646–649.
16. Young RP, Hopkins RJ, Hay BA, Whittington CF, Epton MJ, Gamble
GD. FAM13A locus in COPD is independently associated with lung
cancer—evidence of a molecular genetic link between COPD and
lung cancer. Appl Clin Genet 2010;4:1–10.
17. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more
efficient than replication-based analysis for two-stage genome-wide
association studies. Nat Genet 2006;38:209–213.
18. Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP,
Demeo DL, Sylvia JS, Ziniti J, Laird NM, et al.; NETT Genetics, ICGN,
ECLIPSE and COPDGene Investigators. Risk loci for chronic
obstructive pulmonary disease: a genome-wide association study
and meta-analysis. Lancet Respir Med 2014;2:214–225.
19. Castaldi PJ, Cho MH, Litonjua AA, Bakke P, Gulsvik A, Lomas DA,
Anderson W, Beaty TH, Hokanson JE, Crapo JD, et al.; COPDGene
and Eclipse Investigators. The association of genome-wide
significant spirometric loci with chronic obstructive pulmonary disease
susceptibility. Am J Respir Cell Mol Biol 2011;45:1147–1153.
20. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, Zhao
JH, Ramasamy A, Zhai G, Vitart V, et al.; Wellcome Trust Case
Control Consortium; NSHD Respiratory Study Team. Genome-wide
association study identifies five loci associated with lung function.
Nat Genet 2010;42:36–44.
21. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W,
Zhai G, Zhao JH, Smith AV, Huffman JE, et al.; Genome-wide
association and large-scale follow up identifies 16 new loci
influencing lung function. Nat Genet 2011;43:1082–1090.
22. Hancock DB, Soler Artigas M, Gharib SA, Henry A, Manichaikul A,
Ramasamy A, Loth DW, Imboden M, Koch B, McArdle WL, et al.
Genome-wide joint meta-analysis of SNP and SNP-by-smoking
interaction identifies novel loci for pulmonary function. PLoS Genet
2012;8:e1003098.
23. Liu S, Song Y. Building genetic scores to predict risk of complex
diseases in humans: is it possible? Diabetes 2010;59:2729–2731.
24. Young RP, Hopkins RJ, Hay BA, Gamble GD. Joint effect of single-
nucleotide polymorphisms and smoking exposure in chronic
obstructive pulmonary disease risk. Am J Respir Crit Care Med 2012;
185:683, author reply 683–684.
25. Soler Artigas M, Wain LV, Repapi E, Obeidat M, Sayers I, Burton PR,
Johnson T, Zhao JH, Albrecht E, Dominiczak AF, et al.; Medical
Research Council National Survey of Health and Development
(NSHD) Respiratory Study Team; SpiroMeta Consortium. Effect of
five genetic variants associated with lung function on the risk of
chronic obstructive lung disease, and their joint effects on lung
function. Am J Respir Crit Care Med 2011;184:786–795.
26. Zhou X, Baron RM, Hardin M, Cho MH, Zielinski J, Hawrylkiewicz I,
Sliwinski P, Hersh CP, Mancini JD, Lu K, et al. Identification of a
chronic obstructive pulmonary disease genetic determinant that
regulates HHIP. Hum Mol Genet 2012;21:1325–1335.
27. Zhu G, Warren L, Aponte J, Gulsvik A, Bakke P, Anderson WH, Lomas
DA, Silverman EK, Pillai SG; International COPD Genetics Network
(ICGN) Investigators. The SERPINE2 gene is associated with chronic
obstructive pulmonary disease in two large populations. Am J Respir
Crit Care Med 2007;176:167–173.
28. Patel BD, Coxson HO, Pillai SG, Agustı´ AG, Calverley PM, Donner CF,
Make BJ, Mu¨ller NL, Rennard SI, Vestbo J, et al.; International
COPD Genetics Network. Airway wall thickening and emphysema
show independent familial aggregation in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2008;178:500–505.
29. Silverman EK, Weiss ST, Drazen JM, Chapman HA, Carey V, Campbell
EJ, Denish P, Silverman RA, Celedon JC, Reilly JJ, et al. Gender-
related differences in severe, early-onset chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2000;162:
2152–2158.
30. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH,
Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of
COPD (COPDGene) study design. COPD 2010;7:32–43.
31. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan
G, Knobil K, Lomas DA, MacNee W, et al.; ECLIPSE investigators.
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-
points (ECLIPSE). Eur Respir J 2008;31:869–873.
32. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A,
Weinmann G, Wood DE; National Emphysema Treatment Trial
Research Group. A randomized trial comparing lung-volume-
reduction surgery with medical therapy for severe emphysema. N
Engl J Med 2003;348:2059–2073.
33. Bell B, Rose CL, Damon A. The Normative Aging Study: an
interdisciplinary and longitudinal study of health and aging. Int J
Aging Hum Dev 1972;3:5–17.
34. Sørheim IC, Johannessen A, Grydeland TB, Omenaas ER, Gulsvik A,
Bakke PS. Case–control studies on risk factors for chronic obstructive
pulmonary disease: how does the sampling of the cases and
controls affect the results? Clin Respir J 2010;4:89–96.
ORIGINAL RESEARCH
Busch, Hobbs, Zhou, et al.: Genetic Association and Risk Scores in COPD 45
35. Hobbs BD, Parker MM, Chen H, Lao T, Hardin M, Qiao D,
Hawrylkiewicz I, Sliwinski P, Yim JJ, Kim WJ, et al.; NETT Genetics
Investigators; ECLIPSE Investigators; COPDGene Investigators;
International COPD Genetics Network Investigators. Exome array
analysis identifies a common variant in IL27 associated with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2016;
194:48–57.
36. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ.
Second-generation PLINK: rising to the challenge of larger and richer
datasets. Gigascience 2015;4:7.
37. Chen MH, Yang Q. GWAF: an R package for genome-wide association
analyses with family data. Bioinformatics 2010;26:580–581.
38. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis
of genomewide association scans. Bioinformatics 2010;26:
2190–2191.
39. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante
KD, Franceschini N, van Durme YM, Chen TH, Barr RG, et al. Meta-
analyses of genome-wide association studies identify multiple loci
associated with pulmonary function. Nat Genet 2010;42:45–52.
40. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Mu¨ller M.
pROC: an open-source package for R and S1 to analyze and compare
ROC curves. BMC Bioinformatics 2011;12:77.
41. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library
for genome-wide association analysis. Bioinformatics 2007;23:
1294–1296.
42. Hobbs BD, Hardin M, Hawrylkiewicz I, Sliwinski P, Yim JJ, Kim WJ, Kim
DK, Agusti A, Make BJ, Calverley PM, et al. Coding variant
associations with lung function and COPD using an exome array.
Presented at the American Thoracic Society 2015 International
Conference, Denver, Colorado; 2015.
43. GTEx Consortium. Human genomics: the Genotype-Tissue Expression
(GTEx) pilot analysis: multitissue gene regulation in humans. Science
2015;348:648–660.
44. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin
states, conservation, and regulatory motif alterations within sets of
genetically linked variants. Nucleic Acids Res 2012;40:D930–D934.
45. Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, OwenMC, Vaughan L,
Boswell DR. Structure and variation of human a1-antitrypsin. Nature
1982;298:329–334.
46. Wu Y, Foreman RC. The molecular genetics of a1 antitrypsin
deficiency. BioEssays 1991;13:163–169.
47. Cho MH, Castaldi PJ, Hersh CP, Hobbs BD, Barr RG, Tal-Singer R,
Bakke P, Gulsvik A, San Jose´ Este´par R, Van Beek EJ, et al.;
NETT Genetics, ECLIPSE, and COPDGene Investigators.
A genome-wide association study of emphysema and airway
quantitative imaging phenotypes. Am J Respir Crit Care Med 2015;
192:559–569.
48. Sørheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI,
Campbell EJ, Agustı´ A, Calverley PM, Donner CF, et al. a1-
Antitrypsin protease inhibitor MZ heterozygosity is associated
with airflow obstruction in two large cohorts. Chest 2010;138:
1125–1132.
49. Thun GA, Imboden M, Ferrarotti I, Kumar A, Obeidat M, Zorzetto M,
Haun M, Curjuric I, Couto Alves A, Jackson VE, et al. Causal and
synthetic associations of variants in the SERPINA gene cluster with
a1-antitrypsin serum levels. PLoS Genet 2013;9:e1003585.
50. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS.
Evaluating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond. Stat Med 2008;
27:157–172; discussion 207–112.
51. Hu R, Ouyang Q, Dai A, Tan S, Xiao Z, Tang C. Heat shock protein 27
and cyclophilin A associate with the pathogenesis of COPD.
Respirology 2011;16:983–993.
52. Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: a key player for
human disease. Cell Death Dis 2013;4:e888.
53. Davis CA, Haberland M, Arnold MA, Sutherland LB, McDonald OG,
Richardson JA, Childs G, Harris S, Owens GK, Olson EN.
PRISM/PRDM6, a transcriptional repressor that promotes the
proliferative gene program in smooth muscle cells. Mol Cell Biol
2006;26:2626–2636.
54. Jostins L, Barrett JC. Genetic risk prediction in complex disease. Hum
Mol Genet 2011;20:R182–R188.
55. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M,
Kivima¨ki M, Humphries SE. Utility of genetic and non-genetic risk
factors in prediction of type 2 diabetes: Whitehall II prospective
cohort study. BMJ 2010;340:b4838.
56. Lange P, Celli B, Agustı´ A, Boje Jensen G, Divo M, Faner R, Guerra S,
Marott JL, Martinez FD, Martinez-Camblor P, et al. Lung-function
trajectories leading to chronic obstructive pulmonary disease. N Engl
J Med 2015;373:111–122.
57. Jackson VE, Ntalla I, Sayers I, Morris R, Whincup P, Casas JP, Amuzu A,
Choi M, Dale C, Kumari M, et al. Exome-wide analysis of rare coding
variation identifies novel associations with COPD and airflow limitation
in MOCS3, IFIT3 and SERPINA12. Thorax 2016;71:501–509.
58. Soler Artigas M, Wain LV, Miller S, Kheirallah AK, Huffman JE, Ntalla I,
Shrine N, Obeidat M, Trochet H, McArdle WL, et al.; UK BiLEVE.
Sixteen new lung function signals identified through 1000 Genomes
Project reference panel imputation. Nat Commun 2015;6:8658.
ORIGINAL RESEARCH
46 American Journal of Respiratory Cell and Molecular Biology Volume 57 Number 1 | July 2017
